Tirofiban is a platelet aggregation inhibitor used to prevent thrombotic events in non-ST elevated acute coronary syndrome. Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery.
- Mechanism
- Curator reviewed
Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of tirofiban.
- Primary indication
- For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.Curator reviewed · 2 structured indications
- Formula / weight
- C22H36N2O5S · 440.597 g/mol (avg)
- First approval
- Canada, 2013 · United States, 1998
- Code names
- MK 383
- Brand names
Resolves to
COKMIXFXJJXBQG-NRFANRHFSA-NSMILESCCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=OWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Tirofiban, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account